Literature DB >> 16938889

Inactivation of JNK1 enhances innate IL-10 production and dampens autoimmune inflammation in the brain.

Elise H Tran1, Yasu-Taka Azuma, Manchuan Chen, Claire Weston, Roger J Davis, Richard A Flavell.   

Abstract

Environmental insults such as microbial pathogens can contribute to the activation of autoreactive T cells, leading to inflammation of target organs and, ultimately, autoimmune disease. Various infections have been linked to multiple sclerosis and its animal counterpart, autoimmune encephalomyelitis. The molecular process by which innate immunity triggers autoreactivity is not currently understood. By using a mouse model of multiple sclerosis, we found that the genetic loss of the MAPK, c-Jun N-terminal kinase 1 (JNK1), enhances IL-10 production, rendering innate myeloid cells unresponsive to certain microbes and less capable of generating IL-17-producing, encephalitogenic T cells. Moreover, JNK1-deficient central nervous system myeloid cells are unable to respond to effector T cell inflammatory cytokines, preventing further progression to neuroinflammation. Thus, we have identified the JNK1 signal transduction pathway in myeloid cells to be a critical component of a regulatory circuit mediating inflammatory responses in autoimmune disease. Our findings provide further insights into the pivotal MAPK-regulated network of innate and adaptive cytokines in the progression to autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16938889      PMCID: PMC1569184          DOI: 10.1073/pnas.0601155103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  Antibody directed against mannan of the Mycobacterium tuberculosis cell envelope provokes blood-brain barrier breakdown.

Authors:  I J Namer; J Steibel
Journal:  J Neuroimmunol       Date:  2000-02-01       Impact factor: 3.478

2.  Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis.

Authors:  A Flügel; T Berkowicz; T Ritter; M Labeur; D E Jenne; Z Li; J W Ellwart; M Willem; H Lassmann; H Wekerle
Journal:  Immunity       Date:  2001-05       Impact factor: 31.745

Review 3.  Interleukin-10 and the interleukin-10 receptor.

Authors:  K W Moore; R de Waal Malefyt; R L Coffman; A O'Garra
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

4.  Shiga toxin 1-induced activation of c-Jun NH(2)-terminal kinase and p38 in the human monocytic cell line THP-1: possible involvement in the production of TNF-alpha.

Authors:  Gregory H Foster; Vernon L Tesh
Journal:  J Leukoc Biol       Date:  2002-01       Impact factor: 4.962

5.  Critical involvement of OX40 ligand signals in the T cell priming events during experimental autoimmune encephalomyelitis.

Authors:  L C Ndhlovu; N Ishii; K Murata; T Sato; K Sugamura
Journal:  J Immunol       Date:  2001-09-01       Impact factor: 5.422

Review 6.  Mac-1(+) myelopoiesis induced by CFA: a clue to the paradoxical effects of IFN-gamma in autoimmune disease models.

Authors:  P Matthys; K Vermeire; A Billiau
Journal:  Trends Immunol       Date:  2001-07       Impact factor: 16.687

7.  JNK1 is required for T cell-mediated immunity against Leishmania major infection.

Authors:  S L Constant; C Dong; D D Yang; M Wysk; R J Davis; R A Flavell
Journal:  J Immunol       Date:  2000-09-01       Impact factor: 5.422

8.  Cell type-specific activation of mitogen-activated protein kinases by CpG-DNA controls interleukin-12 release from antigen-presenting cells.

Authors:  H Häcker; H Mischak; G Häcker; S Eser; N Prenzel; A Ullrich; H Wagner
Journal:  EMBO J       Date:  1999-12-15       Impact factor: 11.598

9.  c-Jun NH2-terminal kinase (JNK)1 and JNK2 have similar and stage-dependent roles in regulating T cell apoptosis and proliferation.

Authors:  K Sabapathy; T Kallunki; J P David; I Graef; M Karin; E F Wagner
Journal:  J Exp Med       Date:  2001-02-05       Impact factor: 14.307

10.  Requirement of tumor necrosis factor receptor-associated factor (TRAF)6 in interleukin 17 signal transduction.

Authors:  R Schwandner; K Yamaguchi; Z Cao
Journal:  J Exp Med       Date:  2000-04-03       Impact factor: 14.307

View more
  15 in total

1.  Integration of MicroRNA databases to study MicroRNAs associated with multiple sclerosis.

Authors:  Charlotte Angerstein; Michael Hecker; Brigitte Katrin Paap; Dirk Koczan; Madhan Thamilarasan; Hans-Jürgen Thiesen; Uwe Klaus Zettl
Journal:  Mol Neurobiol       Date:  2012-05-02       Impact factor: 5.590

2.  JNK1, but not JNK2, is required in two mechanistically distinct models of inflammatory arthritis.

Authors:  Katja Denninger; Susanne Rasmussen; Jeppe Madura Larsen; Catrine Orskov; Steen Seier Poulsen; Poul Sørensen; Jan Pravsgaard Christensen; Harald Illges; Niels Odum; Tord Labuda
Journal:  Am J Pathol       Date:  2011-08-11       Impact factor: 4.307

3.  Allosteric Modulation of JNK Docking Site Interactions with ATP-Competitive Inhibitors.

Authors:  Chloe K Lombard; Audrey L Davis; Takayuki Inukai; Dustin J Maly
Journal:  Biochemistry       Date:  2018-09-25       Impact factor: 3.162

Review 4.  IL-10 production by CD4+ effector T cells: a mechanism for self-regulation.

Authors:  D Jankovic; D G Kugler; A Sher
Journal:  Mucosal Immunol       Date:  2010-03-03       Impact factor: 7.313

5.  JNK-1 deficiency limits macrophage-mediated antigen-induced arthritis.

Authors:  Monica Guma; Lisa M Ronacher; Gary S Firestein; Michael Karin; Maripat Corr
Journal:  Arthritis Rheum       Date:  2011-06

Review 6.  Cell type-specific regulation of IL-10 expression in inflammation and disease.

Authors:  Christian M Hedrich; Jay H Bream
Journal:  Immunol Res       Date:  2010-07       Impact factor: 2.829

7.  A small molecule bidentate-binding dual inhibitor probe of the LRRK2 and JNK kinases.

Authors:  Yangbo Feng; Jeremy W Chambers; Sarah Iqbal; Marcel Koenig; HaJeung Park; Lisa Cherry; Pamela Hernandez; Mariana Figuera-Losada; Philip V LoGrasso
Journal:  ACS Chem Biol       Date:  2013-06-10       Impact factor: 5.100

8.  c-Jun N-Terminal Kinase in Inflammation and Rheumatic Diseases.

Authors:  Monica Guma; Gary S Firestein
Journal:  Open Rheumatol J       Date:  2012-09-07

9.  Experimental coronavirus retinopathy (ECOR): retinal degeneration susceptible mice have an augmented interferon and chemokine (CXCL9, CXCL10) response early after virus infection.

Authors:  Barbara Detrick; Maria Teresa Lee; Marian S Chin; Laura C Hooper; Chi-Chao Chan; John J Hooks
Journal:  J Neuroimmunol       Date:  2007-11-26       Impact factor: 3.478

10.  Glatiramer acetate treatment negatively regulates type I interferon signaling.

Authors:  Nicolas Molnarfi; Thomas Prod'homme; Ulf Schulze-Topphoff; Collin M Spencer; Martin S Weber; Juan C Patarroyo; Patrice H Lalive; Scott S Zamvil
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-11-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.